Skip to main content

Table 6 Baseline deterministic cost, effectiveness and cost-effectiveness results comparing the triple single-pill combination (V/A/H) with each possible dual combination

From: Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components

Treatment alternative

Cost (€)

Incremental Cost (€)

Effectiveness (QALYs/LYs)

Incremental effectiveness (QALYs/LYs)

ICER (€/QALY or €/LY)

In QALYs

     

 V/A/H

16,525.25

 

12.76

  

 V/H

14,124.74

2400.51

12.61

0.15

16,192.40

 V/A

15,480.46

1044.79

12.64

0.12

8690.13

 A/H

11,690.08

4835.17

12.38

0.38

12,694.89

In LYs

     

 V/A/H

16,525.25

 

15.99

  

 V/H

14,124.74

2400.51

15.81

0.18

7456.95

 V/A

15,480.46

1044.79

15.85

0.14

4073.82

 A/H

11,690.08

4835.17

15.50

0.49

5002.20

  1. Abbreviations: V valsartan, H hydrochlorothiazide, A amlodipine, QALY quality-adjusted life year, LY life year, ICER incremental cost-effectiveness ratio